Windtree Therapeutics Inc (WINT) Return on Assets ROA from the third quarter of 2025 to third quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Windtree Therapeutics Inc  (WINT)


Windtree Therapeutics Inc's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Windtree Therapeutics Inc's ROA in the third quarter of 2025?
Windtree Therapeutics Inc recorded a cumulative net loss of $-41 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -160.09%.

However, within the Healthcare sector 841 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2025 from 4088 to 4537.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Total Assets Change -47.49 % 11.83 % -11.08 % -14.53 % -15.88 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -41 -15 -16 -2 -9
Return On Assets (TTM) -160.09 % -50.93 % -56.83 % -6.39 % -30.05 %
WINT's Total Ranking # 4537 # 4088 # 4231 # 3655 # 3919
Total Assets (TTM) in million 16 32 27 28 30
Seq. Total Assets Change -49.76 % 18.9 % -3.77 % -8.64 % 6.99 %
Seq. Net Income Change - - - - -

WINT's 5 Years Annual ROA >> Back to WINT Management Effectiveness >> Compare WINT ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 129
Sector # 842
Overall # 4483

Return On Assets Statistics
High Average Low
-6.37 %
-106.08 %
-352.4 %
(Dec 31 2024)   (Sep 30 2018)



  News about Windtree Therapeutics Inc Return on Assets ROA

A Beacon of Hope Windtree Therapeutics Pioneers Advances in Cardiogenic Shock Management

In the annals of medical advancement, one can scarcely overlook the titanic struggles and triumphs that bespeak the human endeavour to alleviate suffering. It is with a spirit of anticipation that we herald the promising news emerging from Windtree Therapeutics Inc. whose recent announcement lays forth the positive topline results gleaned from the Phase 2b SEISMiC Extension Study of Istaroxime; a pioneering compound poised to revolutionize the management of early cardiogenic shock.In recent weeks, the results of this pivotal study have captivated the attention of both the scientific community and the discerning public, as they reveal encouraging improvements in the primary endpoint the systolic blood pressure profile over a span of six hours. Such an achievement, one dares say, may illuminate the path to enhanced patient outcomes in a condition that hath long been the nemesis of clinicians and caregivers alike. Additionally, significant ameliorations were observed across various secondary endpoint assessments, reinforcing the therapeutic potential of Istaroxime in the management of this grave affliction.

Windtree Therapeutics Inc Navigating Volatility with Promising Prospects

Amidst the ever-changing landscape of the healthcare sector, Windtree Therapeutics Inc (NASDAQ: WINT) has emerged as a key player with a potential for future returns. This Philadelphia-based biopharmaceutical company specializes in the development of novel products for respiratory diseases and other critical conditions. While the stock has experienced volatility in recent times, several developments suggest that Windtree Therapeutics is well-positioned for success.On June 26, 2020, Ladenburg Thalmann raised the price target for Windtree Therapeutics stock to a Buy, indicating a positive outlook on the company s potential. This improvement in rating further bolsters investor confidence in the company s prospects. Additionally, the announcement of a $1 million private placement of Series C Convertible financing demonstrates Windtree Therapeutics commitment to fueling growth and expanding its operations.



Financial Statements
Windtree Therapeutics Inc's Assets $ 16 million WINT's Balance sheet
Windtree Therapeutics Inc's Income $ -28 million Quarterly WINT's Income Statement
WINT's Income by Division See WINT's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020
Y / Y Total Assets Change -14.53 % -14.55 % -49.06 % -33.75 % -5.12 %
Total Assets in million 28 33 38 75 113
Y / Y Net Income Change - - - - -
Net Income in million -2 -20 -39 -68 -33
Annual Return On Assets -6.71 % -62.33 % -102.91 % -90.44 % -28.85 %

WINT's 5 Years Annual ROA >> Back to WINT Management Effectiveness >> Compare WINT ROA to its Competitors



More Return On Assets Ratios
WINT's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
WINT's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for WINT's Competitors
Subscribers only: Roa for Windtree Therapeutics Inc's Suppliers
Subscribers only: Return On Assets for WINT's Customers

You may also want to know
WINT's Roi WINT's Inventory Turnover Ratio WINT's Growth Rates WINT's Dividend Comparisons
WINT's Profitability Ratios WINT's Asset Turnover Ratio WINT's Dividend Growth
WINT's Roe WINT's Valuation Ratios WINT's Financial Strength Ratios WINT's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector ROA

Date modified: 2026-08-29T17:25:51+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.